SCHEMBL5422992

SCHEMBL5422992

COCCCNC(=O)c1ccc(C)nc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.74
ALDH1A1 P00352 5/20 0.69
TDP1 Q9NUW8 1/20 0.59
CYP19A1 P11511 1/20 0.58
GSK3B P49841 1/20 0.56
HDAC1 Q13547 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
POLB P06746 1/20 0.55
ALOX15 P16050 1/20 0.55
NPC1 O15118 3/20 0.53
RAB9A P51151 2/20 0.53
KMT2A Q03164 1/20 0.53
GABRA5 P31644 1/20 0.52
HPGD P15428 1/20 0.51
GAA P10253 1/20 0.50
ALOX12 P18054 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5423126 0.91 KDM4E (0.68) KDM4EALDH1A1TDP1CYP19A1GSK3B
SCHEMBL5426580 0.86 KDM4E (0.67) KDM4EALDH1A1TDP1CYP19A1GSK3B
SCHEMBL9561573 0.85 ALDH1A1 (0.69) KDM4EALDH1A1POLBNPC1RAB9A
SCHEMBL16109895 0.84 ALDH1A1 (0.67) KDM4EALDH1A1TDP1NPC1RAB9A
SCHEMBL12588233 0.84 KDM4E (0.76) KDM4EALDH1A1TDP1CYP19A1GSK3B
SCHEMBL5426967 0.84 KDM4E (0.76) KDM4EALDH1A1TDP1CYP19A1HDAC1
SCHEMBL18116704 0.82 KDM4E (0.74) KDM4EALDH1A1TDP1CYP19A1HDAC1
SCHEMBL16111493 0.82 ALDH1A1 (0.63) KDM4EALDH1A1HDAC6NPC1RAB9A
SCHEMBL5423478 0.81 KDM4E (0.72) KDM4EALDH1A1TDP1CYP19A1HDAC1
SCHEMBL12143427 0.81 KDM4E (0.72) KDM4EALDH1A1TDP1CYP19A1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US claimed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP claimed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US claimed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO claimed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO claimed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US claimed
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-22 US disclosed
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS HAVIV FORTUNA 2007-02-08 US disclosed
EP-1551404-A2 METHOD OF INHIBITING ANGIOGENESIS Abbott Laboratories (US) 2005-07-13 EP disclosed
US-20040116479-A1 Method of inhibiting angiogenesis ABBOTT LABORATORIES 2004-06-17 US disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 WO disclosed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032527-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 KDM4E 3402/4885ALDH1A1 837/4885TDP1 4517/4885
US-20070043089-A1 METHOD OF INHIBITING ANGIOGENESIS PGF, VEGFA, FLT4 KDM4E 3402/4885ALDH1A1 837/4885TDP1 4517/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 KDM4E 3429/4885ALDH1A1 450/4885TDP1 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.